BHC

Bausch Health Companies Inc., formerly Valeant Pharmaceuticals, is a global pharmaceutical and medical device company developing and marketing products primarily in gastroenterology, dermatology, and eye health. The company operates through segments including Bausch + Lomb (eye health products including contact lenses, solutions, and surgical devices), Salix (gastroenterology products), and Dermatology. Bausch Health owns established pharmaceutical brands and medical devices sold globally through diverse channels. The company became notorious in the mid-2010s for aggressive price increases and accounting practices under previous management, leading to investigations, lawsuits, and massive stock declines. Headquartered in Laval, Quebec, Bausch Health has worked to restore its reputation and reduce massive debt accumulated through acquisitions. The company has divested non-core assets and separated Bausch + Lomb through a partial IPO. Bausch Health faces patent expirations, generic competition, litigation overhangs, and a challenging capital structure. The company continues to focus on new product launches, operational improvements, and debt reduction while managing its complex legacy issues.